Market Risk from Fluctuations in Interest Rates, Securities Prices and Foreign Exchange Rates
First written in FY2016. 11 of 32 entries say "Worsened", first in FY2018. Latest entry: 2026-08-03.
The Yamagata Bank moved to the "Worse" side of this theme in 2018, 1 year before the typical company in this theme (2019).
The whole theme swung hardest in 2019: 13 of 16 companies on the "Worse" side.
3 other companies' latest entry also says "Mitigated".
- 2026-08-03MitigatedEarnings
「Valuation gains and losses on other securities increased by ¥12.7 billion year on year to a valuation loss of ¥8.3 billion, as the increase in valuation gains and losses on equities and other securities outweighed the decline in valuation gains and losses on bonds.」
Valuation losses on other securities narrowed from the loss in the same period of the previous year, improving the market valuation difference. - FY2026WorsenedAnnual report
「As of 31 March 2026 (consolidated fiscal year-end), market risk exposure (estimated loss) was ¥51,458 million in total, compared with ¥43,054 million at the end of the previous consolidated fiscal year.」
Estimated market risk exposure increased from the end of the previous fiscal year. Meanwhile, the valuation difference on other securities improved from a negative ¥20,957 million to a negative ¥10,359 million. - 2026-05-15MitigatedEarnings
「Valuation gains and losses on other securities increased by ¥12.2 billion year on year to a valuation loss of ¥15.2 billion, as the increase in valuation gains and losses on equities and other securities outweighed the decline in valuation gains and losses on bonds.」
Valuation losses on other securities remained, but valuation gains and losses improved by ¥12.2 billion from the previous fiscal year. - FY2026-H1MitigatedAnnual report
「Valuation differences on available-for-sale securities △20,957 △9,386」
Valuation differences on available-for-sale securities improved from negative ¥20,957 million at the end of the previous fiscal year to negative ¥9,386 million at the end of the interim period. Comprehensive income also shifted from negative ¥763 million in the same period of the previous year to a surplus of ¥15,577 million. - FY2025-H1WorsenedAnnual report
「Valuation differences on available-for-sale securities △10,567 △13,228」
Valuation differences on available-for-sale securities deteriorated from negative ¥10,567 million at the end of the previous fiscal year to negative ¥13,228 million at the end of the interim period. Impairment losses on securities during the interim consolidated period amounted to ¥50 million, all on corporate bonds. - FY2024WorsenedAnnual report
「As of 31 March 2024, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥53,876 million, compared with ¥51,014 million at the end of the previous consolidated fiscal year.」
Estimated market risk exposure increased from ¥51,014 million at the end of the previous fiscal year to ¥53,876 million. Meanwhile, valuation differences on available-for-sale securities improved from negative ¥18,150 million to negative ¥10,567 million. - FY2024-Q3MitigatedAnnual report
「Valuation differences on available-for-sale securities △ 29,377 4,013」
Valuation differences on available-for-sale securities shifted from a ¥29,377 million loss in the same period of the previous year to a ¥4,013 million gain during the cumulative third quarter. The valuation loss position associated with market price fluctuations improved. - FY2024-Q2WorsenedAnnual report
「Valuation differences on available-for-sale securities △ 18,150 △ 21,537」
Valuation differences on available-for-sale securities deteriorated from negative ¥18,150 million at the end of the previous fiscal year to negative ¥21,537 million at the end of the interim period, with valuation losses associated with market price fluctuations increasing. - FY2024-Q1MaterialisedAnnual report
「Impairment losses during the previous consolidated fiscal year amounted to ¥5 million, all on equities. Impairment losses during the cumulative first quarter amounted to ¥30 million, all on corporate bonds.」
Impairment losses on securities increased from ¥5 million in the previous fiscal year to ¥30 million during the cumulative first quarter, with actual impairment losses recognized on corporate bonds. Meanwhile, valuation differences on available-for-sale securities narrowed from negative ¥18,150 million at the end of the previous fiscal year to negative ¥13,666 million. - FY2023WorsenedAnnual report
「As of 31 March 2023, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥51,014 million, compared with ¥45,460 million at the end of the previous consolidated fiscal year.」
Estimated market risk exposure increased from ¥45,460 million at the end of the previous fiscal year to ¥51,014 million. - FY2023-Q3WorsenedAnnual report
「Valuation differences on available-for-sale securities 5,282 △ 29,377」
Valuation differences on available-for-sale securities deteriorated from a ¥5,282 million gain in the same period of the previous year to a ¥29,377 million loss, reflecting market price fluctuations. - FY2023-Q2WorsenedAnnual report
「Valuation differences on available-for-sale securities 6,315 △ 18,719」
Valuation differences on available-for-sale securities shifted from a ¥6,315 million valuation gain at the end of the previous fiscal year to an ¥18,719 million valuation loss at the end of the interim period. Valuation losses associated with market price fluctuations increased. - FY2023-Q1MaterialisedAnnual report
「Valuation differences on available-for-sale securities 6,315 △ 10,583」
Valuation differences on available-for-sale securities shifted from a ¥6,315 million valuation gain at the end of the previous fiscal year to a ¥10,583 million valuation loss at the end of the first quarter, indicating that valuation losses related to market price fluctuations had actually occurred. - FY2022WorsenedAnnual report
「As of 31 March 2022, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥45,460 million, compared with ¥44,492 million at the end of the previous consolidated fiscal year. Impairment losses during the previous consolidated fiscal year amounted to ¥346 million. Impairment losses during the current consolidated fiscal year amounted to ¥483 million, all on equities.」
Estimated market risk exposure increased from the end of the previous fiscal year, while impairment losses on securities also increased from ¥346 million to ¥483 million. - FY2022-Q3MaterialisedAnnual report
「Impairment losses recognized during the cumulative third quarter amounted to ¥262 million, including ¥262 million on equities.」
The company recognized ¥262 million in impairment losses on equities during the cumulative third quarter for securities affected by fluctuations in market prices and other factors, with such losses continuing to occur. - FY2022-Q2MaterialisedAnnual report
「Impairment losses recognized during the interim consolidated period amounted to ¥281 million, including ¥281 million on equities.」
The company recognized ¥281 million in impairment losses on equities during the interim consolidated period for securities affected by fluctuations in market prices and other factors, with such losses continuing to occur. - FY2022-Q1MaterialisedAnnual report
「Impairment losses recognized during the cumulative first quarter amounted to ¥283 million, including ¥283 million on equities.」
The company recognized ¥283 million in impairment losses on equities during the cumulative first quarter for securities affected by fluctuations in market prices and other factors. - FY2021MaterialisedAnnual report
「As of 31 March 2021, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥44,492 million, compared with ¥53,187 million at the end of the previous consolidated fiscal year. No impairment losses were recognized during the previous consolidated fiscal year. Impairment losses recognized during the current consolidated fiscal year amounted to ¥346 million, including ¥196 million on equities and ¥150 million on corporate bonds.」
Estimated market risk exposure decreased from the end of the previous fiscal year, while impairment losses on securities totaled ¥346 million in the current fiscal year, comprising ¥196 million on equities and ¥150 million on corporate bonds. - FY2021-Q3MaterialisedAnnual report
「Impairment losses recognized during the cumulative third quarter amounted to ¥29 million, including ¥29 million on equities.」
The company recognized ¥29 million in impairment losses on equities during the cumulative third quarter for securities affected by fluctuations in market prices and other factors, resulting in an actual loss. - FY2021-Q2MitigatedAnnual report
「No impairment loss was recognized during the previous consolidated fiscal year or the current interim consolidated accounting period.」
The company stated that no impairment losses on securities were recognized during the previous consolidated fiscal year or the interim consolidated period. - FY2020WorsenedAnnual report
「As of 31 March 2020, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥53,187 million, compared with ¥27,579 million at the end of the previous consolidated fiscal year.」
Amid market conditions including volatility associated with the spread of COVID-19, estimated market risk exposure increased substantially from ¥27,579 million to ¥53,187 million. - FY2020-Q3MitigatedAnnual report
「There were no impairment losses during the previous consolidated fiscal year or the cumulative third quarter.」
The company stated that no impairment losses on securities were recognized during the previous consolidated fiscal year or the cumulative third quarter. - FY2019WorsenedAnnual report
「As of 31 March 2019, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥27,579 million, compared with ¥26,579 million at the end of the previous consolidated fiscal year.」
Estimated market risk exposure increased from ¥26,579 million at the end of the previous fiscal year to ¥27,579 million. The company also disclosed VaR calculation assumptions of a 90-day holding period, a 99% confidence interval and a 250-business-day observation period. - FY2019-Q3MaterialisedAnnual report
「Impairment losses recognized during the cumulative third quarter amounted to ¥107 million, including ¥107 million on equities.」
The company recognized ¥107 million in impairment losses on equities during the cumulative third quarter for securities affected by fluctuations in market prices and other factors. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, there were no material changes to, or newly arising risks among, the business and other risks that could materially affect investors’ decisions, compared with the descriptions in the annual securities report for the previous fiscal year.」
The company stated that there were no material changes or new developments from the previous fiscal year relating to market risk arising from fluctuations in interest rates, securities prices and foreign exchange rates. - FY2018WorsenedAnnual report
「As of 31 March 2018, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥26,579 million, compared with ¥26,173 million at the end of the previous consolidated fiscal year.」
Estimated market risk exposure increased from ¥26,173 million at the end of the previous fiscal year to ¥26,579 million. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no newly arising matters that could materially affect investors’ decisions among the matters concerning the business and financial conditions described in this quarterly report, nor any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company stated that there were no material changes or new developments relating to market risk arising from fluctuations in interest rates, securities prices and foreign exchange rates. - FY2018-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, there were no material changes to, or newly arising risks among, the business and other risks that could materially affect investors’ decisions, compared with the descriptions in the annual securities report for the previous fiscal year.」
The company stated that there were no material changes or new developments relating to market risk arising from fluctuations in interest rates, securities prices and foreign exchange rates. - FY2017MitigatedAnnual report
「As of 31 March 2017, the consolidated fiscal year-end, market risk exposure, an estimate of potential losses, totaled ¥26,173 million, compared with ¥31,581 million at the end of the previous consolidated fiscal year.」
Estimated market risk exposure decreased from ¥31,581 million at the end of the previous fiscal year to ¥26,173 million. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no newly arising matters that could materially affect investors’ decisions among the matters concerning the business and financial conditions described in this quarterly report, nor any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company stated that there were no material changes or new developments relating to market risk arising from fluctuations in interest rates, securities prices and foreign exchange rates. - FY2017-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, there were no material changes to, or newly arising risks among, the business and other risks that could materially affect investors’ decisions, compared with the descriptions in the annual securities report for the previous fiscal year.」
The company stated that there were no material changes or new developments relating to market risk compared with the previous year's securities report. - FY2016First statedAnnual report
「As of 31 March 2016, market risk, measured as the estimated loss amount, totaled ¥31.581 billion, compared with ¥23.427 billion at the end of the previous consolidated fiscal year.」
The bank disclosed an increase in estimated market risk from ¥23.427 billion at the previous fiscal year-end to ¥31.581 billion.